
1. Zhonghua Gan Zang Bing Za Zhi. 2021 Oct 20;29(10):948-966. doi:
10.3760/cma.j.cn501113-20210907-00456.

[Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular
carcinoma: a 2021 update].

[Article in Chinese; Abstract available in Chinese from the publisher]

Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical
Association.

With the development of anti-HBV and HCV therapy, experts in related fields
organized by the Liver Cancer Study Group, Chinese Society of Hepatology, Chinese
Medical Association updated "Experts Consensus on Antiviral Therapy for HBV/
HCV-related Hepatocellular Carcinoma" . On the basis of previous expert
recommendations/consensus and the new evidence in recent years, this new
consensus was developed, and the relevant recommendations are provided to
hepatologists, epidemiologists, medical doctors and specialists working in
community service centers and primary health care institutions for guidance of
hepatocellular carcinoma antiviral treatment.

Publisher:
随着抗HBV、HCV治疗学的进展，中华医学会肝病学分会肝癌学组组织相关领域专家对《HBV/HCV相关肝细胞癌抗病毒治疗专家共识》进行了更新。此版共识在以往专家建议
/共识基础上，对近年新证据结果进行分析并形成相关推荐意见，以期为肝病专科、感染科以及这些科室以外从事与肝癌诊疗工作相关的临床医生及社区服务中心、基层医疗机构等相关
工作人员提供指导和参考。.
DOI: 10.3760/cma.j.cn501113-20210907-00456 
PMID: 34814389  [Indexed for MEDLINE]

